Evidence map›Paper›PMID 34351529›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2021

Reduction trend of mcr-1 circulation in Emilia-Romagna Region, Italy.

Carlo Gagliotti, Luca Bolzoni, Edoardo Carretto, Mario Sarti, Enrico Ricchizzi, Simone Ambretti, Agostino Barozzi, Chiara Bracchi, Massimo Confalonieri, Ilaria Menozzi and 17 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. First Detection of theAntibiotics (Basel, Switzerland) · 2026
    Article
  2. First Detection ofAntibiotics (Basel, Switzerland) · 2023
    Article
  3. The Clash of the Titans: COVID-19, Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2023
    Article
  4. Article
  5. Article
  6. Spread of theFrontiers in microbiology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Carlo Gagliotti *Agenzia Sanitaria e Sociale Regionale - Regione Emilia-Romagna, Viale Aldo Moro 21, 40127, Bologna, Italy. carlo.gagliotti@regione.emilia-romagna.it.ORCID http://orcid.org/0000-0003-0684-731X
Luca Bolzoni *Risk Analysis and Genomic Epidemiology, Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia-Romagna (IZSLER), Parma, Italy.
Edoardo CarrettoMicrobiologia AUSL Reggio Emilia, Reggio Emilia, Italy.
Mario SartiMicrobiologia AOU Modena, Modena, Italy.
Enrico RicchizziAgenzia Sanitaria e Sociale Regionale - Regione Emilia-Romagna, Viale Aldo Moro 21, 40127, Bologna, Italy.
Simone AmbrettiUnit of Microbiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola, 40138, Bologna, Italy.
Agostino BarozziMicrobiologia AOU Ferrara, Ferrara, Italy.
Chiara BracchiRisk Analysis and Genomic Epidemiology, Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia-Romagna (IZSLER), Parma, Italy.
Massimo ConfalonieriMicrobiologia AUSL Piacenza, Piacenza, Italy.
Ilaria MenozziRisk Analysis and Genomic Epidemiology, Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia-Romagna (IZSLER), Parma, Italy.
Marina MorgantiRisk Analysis and Genomic Epidemiology, Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia-Romagna (IZSLER), Parma, Italy.
Maria Federica PednaMicrobiologia AUSL Romagna, Cesena, Italy.
Vittorio SambriMicrobiologia AUSL Romagna, Cesena, Italy.
Erika ScaltritiRisk Analysis and Genomic Epidemiology, Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia-Romagna (IZSLER), Parma, Italy.
Roberta SchiavoMicrobiologia AUSL Piacenza, Piacenza, Italy.
Laura SolianiRisk Analysis and Genomic Epidemiology, Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia-Romagna (IZSLER), Parma, Italy.
Martina TambassiRisk Analysis and Genomic Epidemiology, Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia-Romagna (IZSLER), Parma, Italy.
Claudia VenturelliMicrobiologia AOU Modena, Modena, Italy.
Carlo BiagettiSPIAR AUSL Romagna, Rimini, Italy.
Rossella ButtazziAgenzia Sanitaria e Sociale Regionale - Regione Emilia-Romagna, Viale Aldo Moro 21, 40127, Bologna, Italy.
Adriana CalderaroDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Chiara CasadioServizio Prevenzione Collettiva e Sanità Pubblica, Direzione Generale Cura della Persona, Salute e Welfare, Bologna, Italy.
Marianna MeschiariMalattie Infettive AOU Modena, Modena, Italy.
Fabio TumiettoMalattie infettive - IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Giuseppe DiegoliServizio Prevenzione Collettiva e Sanità Pubblica, Direzione Generale Cura della Persona, Salute e Welfare, Bologna, Italy.
Stefano PongoliniRisk Analysis and Genomic Epidemiology, Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia-Romagna (IZSLER), Parma, Italy.
Maria Luisa MoroAgenzia Sanitaria e Sociale Regionale - Regione Emilia-Romagna, Viale Aldo Moro 21, 40127, Bologna, Italy.

Funding

Italian Ministry of Health PRC2016004; PRC2017001One Health European Joint Programme (OHEJP); COHESIVE project 773830
6 · The paper itself

Abstract

This study aims to describe trends of mcr-positive Enterobacterales in humans based on laboratory surveillance with a defined catchment population. The data source is the Micro-RER surveillance system, established in Emilia-Romagna region (Italy), to monitor the trend of mcr resistance. Enterobacterales isolates from human clinical samples with minimum inhibitory concentration (MIC) ≥ 2 mg/L for colistin were sent to the study reference laboratory for the detection of mcr genes. Isolates prospectively collected in the period 2018-2020 were considered for the assessment of population rates and trends; further analyses were carried out for the evaluation of clonality and horizontal mcr gene transfer. Previous isolates from local laboratory collection were also described. In the period 2018-2020, 1164 isolates were sent to the reference laboratory, and 51 (4.4%) were confirmed as mcr-positive: 50 mcr-1 (42 Escherichia coli, 6 Klebsiella pneumoniae, 2 Salmonella enterica) and 1 mcr-4 (Enterobacter cloacae). The number of mcr-positive isolates dropped from 24 in the first half of 2018 to 3 in the whole of 2020 (trend p value < 0.001). Genomic analyses showed the predominant role of the horizontal transfer of mcr genes through plasmids or dissemination of transposable elements compared to clonal dissemination of mcr-positive microorganisms. The study results demonstrate a substantial decrease in the circulation of mcr-1 plasmid genes in Emilia-Romagna Region.

Indexed as

Anti-Bacterial AgentsBacterial ProteinsDrug Resistance, BacterialEnterobacteriaceaeEnterobacteriaceae InfectionsEthanolaminephosphotransferaseHumansItalyMicrobial Sensitivity TestsPhylogenyRetrospective StudiesAnti-Bacterial AgentsBacterial ProteinsEthanolaminephosphotransferaseAntibiotic resistanceAntimicrobials for veterinary useClonal disseminationColistinEnterobacteralesHorizontal transferHumansMcrOne Health approach

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.